Pilot study of WT1 peptide vaccine therapy for chemorefractory advanced pancreatic cancer
- Conditions
- Pancreatic cancer
- Registration Number
- JPRN-UMIN000001515
- Lead Sponsor
- Tohoku University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Not provided
1) Patients with uncontrollable infection including active tuberculosis. 2) Patients with severe concurrent disease including malignant hypertension, congestive heart failure, severe coronary disorder, myocardial infarction within 3 months, severe liver cirrhosis, uncontrollable diabetes mellitus, lung fibrosis, interstitial pneumonia, prominent peripheral edeme. 3) Patients who showed severe complication (Grade 3 or more severe according to CTCAE version 3.0) with prior chemotherapy. 4) Patients who require 24 h or more intravenous, transcatheteric nutrition or total parenteral nutrition due to GI symptom. 5) Patients with double cancer. 6) Patients with myelo-dysplastic syndrome or myeopoliferative disease. 7) Pregnant or supposed to be pregnant patient. 8) Patients with past history of severe drug allergy. 9) Patients with severe mental disorder. 10) Patients who is not recommended by attending physician, or trial conductor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safty and toxicity Tumor response (Disease control)
- Secondary Outcome Measures
Name Time Method Immune response